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Abstract
Osteoporosis is a common bone disease that has a strong genetic component. Genome-wide linkage studies have identified
the chromosomal region 3p14-p22 as a quantitative trait locus for bone mineral density (BMD). We have previously
identified associations between variation in two related genes located in 3p14-p22, ARHGEF3 and RHOA, and BMD in
women. In this study we performed knockdown of these genes using small interfering RNA (siRNA) in human osteoblast-like
and osteoclast-like cells in culture, with subsequent microarray analysis to identify genes differentially regulated from a list
of 264 candidate genes. Validation of selected findings was then carried out in additional human cell lines/cultures using
quantitative real-time PCR (qRT-PCR). The qRT-PCR results showed significant down-regulation of the ACTA2 gene, encoding
the cytoskeletal protein alpha 2 actin, in response to RHOA knockdown in both osteoblast-like (P,0.001) and osteoclast-like
cells (P = 0.002). RHOA knockdown also caused up-regulation of the PTH1R gene, encoding the parathyroid hormone 1
receptor, in Saos-2 osteoblast-like cells (P,0.001). Other findings included down-regulation of the TNFRSF11B gene,
encoding osteoprotegerin, in response to ARHGEF3 knockdown in the Saos-2 and hFOB 1.19 osteoblast-like cells (P = 0.003–
0.02), and down-regulation of ARHGDIA, encoding the Rho GDP dissociation inhibitor alpha, in response to RHOA
knockdown in osteoclast-like cells (P,0.001). These studies identify ARHGEF3 and RHOA as potential regulators of a number
of genes in bone cells, including TNFRSF11B, ARHGDIA, PTH1R and ACTA2, with influences on the latter evident in both
osteoblast-like and osteoclast-like cells. This adds further evidence to previous studies suggesting a role for the ARHGEF3
and RHOA genes in bone metabolism.
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Introduction
Osteoporosis is a common and debilitating bone disease that is
characterised by a low bone mineral density (BMD), which leads to
an increased risk of fracture [1]. The disease is particularly
prevalent in postmenopausal women due to a reduction in
oestrogen production, with subsequent effects on bone as well as
intestinal and renal calcium handling [2]. In addition to the effects
of oestrogen, calcium and other environmental factors on bone
structure, there is a strong genetic effect on peak bone mass
(attained in early adult life), bone loss and fracture rates [3,4].
Twin and family studies suggest that 50–90% of the variation in
peak bone mass [5–7] and 25–68% of the variance in osteoporotic
fracture is heritable [4,8,9]. The genome-wide linkage scanning
approach has identified at least 11 replicated quantitative trait loci
(QTL) for BMD [10–12], including the 3p14-p22 region of the
human genome (LOD 1.1–3.5) [11–14].
We have previously identified significant associations between
variation in the RHOA and ARHGEF3 genes, which are both
located within the 3p14-p22 region, and BMD in women [15,16].
The functions of these genes are related, with the product of the
ARHGEF3 gene (the Rho guanine nucleotide exchange factor
(GEF) 3) specifically activating two members of the RhoGTPase
family: RhoA (encoded for by the RHOA gene) and RhoB [17].
RhoA is involved with regulating cytoskeletal dynamics and actin
polymerisation [18] and has been shown to have a role in
osteoblast differentiation [19,20] and osteoclastic bone resorption
[21].
Given the associations that we have previously identified
between the RHOA and ARHGEF3 genes and BMD, coupled
with the evidence in the literature suggesting a role for RhoA in
osteoblasts and osteoclasts, we decided to further investigate the
role of these genes in these particular cell types. Knockdown of the
RHOA and ARHGEF3 genes was achieved using small interfering
RNA (siRNA) in a human osteoblast-like cell line and in osteoclast-
like cells derived from a donor, with subsequent microarray
analysis to identify genes that were differentially regulated.
Replication of selected significant findings was then conducted in
additional human osteoblast-like cell lines and in osteoclast-like
cells from additional donors.
PLOS ONE | www.plosone.org 1 May 2014 | Volume 9 | Issue 5 | e98116
Materials and Methods
Ethics Statement
All subjects that donated blood samples for isolation of
peripheral blood mononuclear cells (PBMCs) provided written
informed consent and the institutional ethics committee of Curtin
University approved the experimental protocol.
Experimental Approach
To identify genes involved in osteoblast and osteoclast function
that are potentially influenced by the RHOA and ARHGEF3 genes,
we examined the influence of knockdown of these two genes on
264 candidate genes in an osteoblast-like cell line and osteoclast-
like cells obtained from a donor, in triplicate, by microarray
analysis. The microarray results showed significant alterations in
the expression of a number of the candidate genes, 7 of which
were studied in greater detail to validate the findings, based on
quantitative real-time PCR (qRT-PCR) studies of the 7 genes in 3
additional osteoblast-like and osteoclast-like cell cultures/lines.
Cell Culture
The osteoblast-like cell lines used for the gene knockdown
experiments included: Saos-2, derived from osteosarcoma tissue
(American Type Culture Collection (ATCC) Nu HTB-85) [22];
hFOB 1.19, derived from immortalised foetal osteoblasts (ATCC
Nu CRL-11372) [23]; and MG-63, derived from osteosarcoma
tissue (ATCC Nu CRL-1427) [24]. These cell lines are all human
in origin and were cultured in DMEM (Sigma-Aldrich, St. Louis,
USA) pH 7.4 supplemented with 4.77 g/l HEPES, 3.7 g/l
NaHCO3, 10% (v/v) foetal bovine serum (FBS) and 1% (v/v)
penicillin/streptomycin (100 units penicillin and 100 mg strepto-
mycin per ml of media). The osteoclast-like cells used in these
studies were differentiated from PBMCs (process described below)
and were cultured in a-MEM (Invitrogen, Carlsbad, USA) pH 7.4
supplemented with 2.2 g/l NaHCO3, 10% (v/v) FBS and 1% (v/
v) penicillin/streptomycin. All cells were cultured at 37uC with 5%
CO2 and the medium was changed every 2–3 days. Total RNA
was harvested from each culture using the RNeasy Mini Kit
(Qiagen, Hilden, Germany) and reverse transcription of the RNA
was performed using the QuantiTect Reverse Transcription Kit
(Qiagen, Hilden, Germany). Quantitation of total RNA was
performed using an ND-1000 spectrophotometer (NanoDrop
Technologies, Wilmington, USA).
Isolation of Peripheral Blood Mononuclear Cells and
Osteoclastogenesis
Osteoclast-like cells were differentiated from PBMCs isolated
from 4 male donors of European descent aged 48615 years (mean
6 SD). Each batch of cells was isolated from 30 ml whole blood
collected in 10 ml K2EDTA Vacutainer tubes (Becton, Dickinson
and Company, Franklin Lakes, USA). Anti-coagulated whole
blood samples were centrifuged at 2,200 rpm for 10 min at room
temperature before buffy coats were collected and diluted to a total
volume of 4 ml with 16phosphate buffered saline (PBS). The cell
suspension was then gently layered over 3 ml of Ficoll-Paque
(Pfizer, New York, USA) before being centrifuged again at
1,600 rpm for 40 min at room temperature. The PBMC layer was
collected and washed by re-suspension in 6 ml 16 PBS and
centrifuged at 800 rpm for 10 min at room temperature. The
wash step was repeated on the cell pellet before the cells were re-
suspended in 5 ml medium supplemented with 10 ng/ml macro-
phage colony stimulating factor (M-CSF) (Invitrogen, Carlsbad,
USA) and seeded directly into either a 24-well tissue culture plate
or 25 cm2 tissue culture flask. After two days, the medium was
replaced with medium supplemented with 10 ng/ml M-CSF and
100 ng/ml receptor activator of nuclear factor kappa-B ligand
(RANKL) (Invitrogen, Carlsbad, USA). The cells were then grown
using this medium formulation for 17 days while osteoclastogenesis
occurred.
Osteoclast-like cells were stained for tartrate resistant acid
phosphatase (TRAP) using a chromogenic TRAP enzyme
substrate to confirm production of the TRAP enzyme as an
indicator of the osteoclast phenotype. This involved washing the
cells with 16 PBS, fixation with 4% (v/v) paraformaldehyde for
15 min, washing 3 times with 16 PBS before incubation with
filtered TRAP stain solution at 37uC for 25 min. The stained cells
were then washed 3 times with 16PBS prior to visualisation using
light microscopy.
siRNA Knockdown
Transfection of cells with siRNA sequences was used to
knockdown expression of the ARHGEF3 and RHOA genes.
Transfections were performed using HiPerFect Transfection
Reagent (Qiagen, Hilden, Germany). Two different siRNA
sequences were used in tandem to knockdown expression of each
gene. There is evidence to suggest that the RhoA protein has a
half-life of up to 31 h [25], therefore a minimum gene knockdown
period of 48 h was used to ensure an effect at the protein level.
Negative controls treated with AllStars Negative Control siRNA
(Qiagen, Hilden, Germany) were included in each experiment. All
knockdown experiments were performed in triplicate. Knockdown
of the ARHGEF3 and RHOA genes did not appear to influence the
proliferation or viability of any of the cell types studied.
Knockdown in Osteoblast-like Cells
siRNA knockdown experiments were performed in 24-well
tissue culture plates. For the Saos-2, hFOB 1.19 and MG-63
osteoblast-like cell lines, each well was seeded with 56104 cells.
Cells were grown for 24 h before fresh medium was added to each
culture and transfections were performed using a final siRNA
concentration of 30 nM with 6 mL transfection reagent per well.
Cells in each well were incubated with the transfection mix for
48 h at 37uC prior to washing with 16PBS and extraction of total
RNA.
Knockdown in Peripheral Blood Mononuclear Cells/
Osteoclast-like Cells
500 mL of freshly isolated PBMCs were aliquoted into 24-well
tissue culture plates. Osteoclastogenesis was stimulated and
confirmed microscopically and biochemically as described previ-
ously by TRAP staining. siRNA knockdown experiments were
performed using a final siRNA concentration of 100 nM with
6 mL transfection reagent per well. Cells in each well were
incubated with the transfection mix for 48 h at 37uC prior to
washing with 16PBS and extraction of total RNA.
RNA Extraction and Microarray Analysis
A total of 18 RNA samples, 9 from Saos-2 and 9 from
osteoclast-like cell cultures (donor 1) were used for the microarray
analysis. Each set of 9 was comprised of 3 cultures treated with
siRNA specific for ARHGEF3, 3 treated with siRNA specific for
RHOA and 3 treated with negative control siRNA. Total RNA was
extracted from each culture using the RNeasy Mini Kit (Qiagen,
Hilden, Germany). The quality and quantity of all RNA samples
was checked prior to microarray analysis using a 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, USA). 10 mL of each RNA
sample was amplified using the TotalPrep RNA Amplification Kit
Influence of ARHGEF3 and RHOA Knockdown
PLOS ONE | www.plosone.org 2 May 2014 | Volume 9 | Issue 5 | e98116
(Applied Biosystems, Foster City, USA) before microarray analysis
was performed using the HumanHT-12 v3 Expression BeadChip
Kit (Illumina, San Diego, USA). The HumanHT-12 BeadChip
profiles the expression of more than 25,000 annotated genes
derived from NCBI RefSeq (Build 36.2) [26]. The complete results
from the microarray analyses performed in this study have been
submitted to The University of Western Australia’s Research Data
Online resource.
Gene Selection
While data were generated for most of the .25,000 genes
included on the microarray, only 264 candidate genes were
selected for statistical analysis in order to limit the potential for
false positives. These candidate genes were selected on the basis of
the following criteria: genes thought to have potentially important
roles in osteoblast (n = 45) or osteoclast function (n= 62), or genes
thought to play a role in the RhoA/ARHGEF3 signalling pathway
(n = 157).
Quantitative Real-time PCR
qRT-PCR was used to determine the degree of gene
knockdown achieved and to validate microarray results for
selected targets. Reverse transcription of RNA samples was first
performed using the QuantiTect Reverse Transcription Kit
(Qiagen, Hilden, Germany). The resulting cDNA was then
amplified using the QuantiFast SYBR Green Kit (Qiagen, Hilden,
Germany) in conjunction with an iQ5 Multicolor Real-Time PCR
Detection System (Bio-Rad, Hercules, USA). cDNA samples were
diluted in 16TE buffer before analysis. QuantiTect Primer Assays
(Qiagen, Hilden, Germany) were used to amplify most gene
transcript sequences. Bioinformatics analysis revealed that the
QuantiTect Primer Assay for the candidate gene ACTA2 amplifies
only one of the two transcript variants for this gene. Therefore, a
custom primer pair was designed for this gene using the web-based
Primer3 software package [27]. The human 18S ribosomal RNA
gene (RRN18S) was selected as an internal reference for this work
to allow for normalisation of the data for variations in the quantity
of cDNA added to each reaction. The reaction efficiency of each
primer pair was calculated by amplifying a 10-fold dilution series
of target sequence across 5 orders of magnitude. This was
performed to confirm that the amplification efficiency of each gene
of interest is no more than 10% from that of the internal reference
as recommended by Schmittgen and Livak [28]. The log template
dilution (x-axis) was plotted against the cycle threshold (CT) value
obtained for each dilution (y-axis) with the slope of the line used
for calculation of amplification efficiency using the equation m=2
(1/log E), where m is the slope of the line and E is the reaction
efficiency. A reaction efficiency of 2.0 equates to a perfect doubling
of amplicon product during each PCR cycle. All reactions were
performed in triplicate with the mean CT value used in the
statistical analysis. Melting-curve analysis was performed on all
real-time PCR products to confirm amplification of a single DNA
sequence. A random selection of PCR products were also
subjected to agarose gel electrophoresis for additional confirma-
tion of the specificity of amplification.
Microarray Statistical Analysis
Differential expression analysis of the microarray data using the
Illumina custom error model was performed using the BeadStudio
v3.4.0 software package (Illumina, San Diego, USA). Samples
treated with the negative control siRNA were specified as the
reference group. The raw microarray gene expression data were
normalised using the quantile normalisation algorithm [29], which
adjusts the sample signals to minimise the influence of variation
arising from non-biological factors (eg. pipetting variation) [30].
Background subtraction was performed on the data to minimise
the variation in background noise between arrays and to remove
signal resulting from non-specific hybridisation [31]. Once
background subtraction has been performed on the data, the
expected signal for unexpressed targets is zero. The data were
corrected for multiple testing using the Benjamini-Hochberg False
Discovery Rate algorithm [32].
Real-time PCR Statistical Analysis
Gene expression ratios were calculated using the comparative
CT method as described by Schmittgen and Livak [28]. Briefly, the
DCT (CT of the test gene2CT of the internal reference) was
calculated for each gene of interest in each sample in the test and
control groups. This figure was then entered into the equation
22DCT with the mean 6 standard error calculated for each of the
test and control groups. 22DCT values for test and control groups
were analysed using an unpaired t-test to determine whether
differences in expression were statistically significant. Combined
22DCT values for the osteoclast-like cells were examined by 2-way
analysis of variance (ANOVA) (note that this combined analysis
was not performed for the osteoblast-like cells due to potential
variation in the maturation state and gene expression profile of
each cell line). Significant associations are defined as P,0.05.
Results
Osteoblast Microarray Results
Knockdown of the ARHGEF3 and RHOA genes was validated in
the Saos-2 cells by qRT-PCR prior to microarray analysis. For the
ARHGEF3 and RHOA genes, 81% and 79% knockdown was
achieved respectively in these cells (Fig. 1A and B). Of the 202
candidate genes examined in the osteoblast-like cells, gene
knockdown resulted in significant changes in expression of 10
genes after adjustment for multiple testing (Table 1). Knockdown
of ARHGEF3 resulted in significant changes to the expression of 8
genes: TNFRSF11B, SP7, ALPL, ANGPTL2, GNA11, MYO9B,
GNAI2 and PFN1. For RHOA knockdown, 2 genes were affected:
PTH1R and ACTA2. Table S1 contains the microarray results for
all of the candidate genes examined in the Saos-2 cells (P values
corrected for multiple testing).
qRT-PCR Validation and Replication of Microarray Results
for Targeted Genes in Osteoblast-like Cell Lines
Both of the differentially regulated genes in the RHOA
knockdown group (PTH1R and ACTA2) and 2 from the ARHGEF3
knockdown group (TNFRSF11B and ALPL) were then selected for
confirmatory and replication studies using qRT-PCR. While the
microarray results suggested that 8 of the 202 genes examined
could potentially be regulated by ARHGEF3, the TNFRSF11B and
ALPL genes were selected based on a number of factors including
their importance to bone metabolism, their level of expression in
the cell type and the size and statistical significance of the
regulatory effect. These 4 genes were thus examined in one
additional replication study experiment in Saos-2 cells as well as in
two additional osteoblast-like cell lines, hFOB 1.19 and MG-63.
For the ARHGEF3 and RHOA genes, 75% and 68% knockdown
was achieved respectively in the replication batch of Saos-2 cells,
75% and 77% respectively in the hFOB 1.19 cells and 84% and
83% respectively in the MG-63 cells (Fig. 1A and B). The average
knockdown achieved across all of the osteoblast-like cell lines as
determined by qRT-PCR was 76.8% for RHOA and 78.7% for
ARHGEF3 (Fig. 1A and B).
Influence of ARHGEF3 and RHOA Knockdown
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The influence of gene knockdown on TNFRSF11B, ALPL,
PTH1R and ACTA2 expression is shown in Fig. 2A–D. A highly
significant down regulation of ACTA2 was observed in response to
RHOA knockdown in each of the osteoblast-like cell lines examined













ARHGEF3 TNFRSF11B Osteoprotegerin 235 308 0.76 ,0.001
SP7 Osterix 434 381 1.14 0.007
ALPL Alkaline
phosphatase
19262 17173 1.12 0.03
ANGPTL2 Angiopoietin-like 2 81 50 1.64 ,0.001
GNA11 Guanine nucleotide binding
protein alpha 11
352 469 0.75 0.002
MYO9B Myosin IXB 165 212 0.78 0.005
GNAI2 Guanine nucleotide binding
protein alpha inhibiting activity polypeptide 2
1106 1330 0.83 0.006
PFN1 Profilin 1 7458 8220 0.91 0.02
RHOA PTH1R Parathyroid hormone 1 receptor 1166 492 2.37 0.002
ACTA2 Alpha 2 actin, smooth muscle 3059 7812 0.39 ,0.001
Expression ratios are given as expression of the gene in the knockdown cultures relative to the negative control cultures. P adjusted for multiple testing.
*FU, fluorescence units.
doi:10.1371/journal.pone.0098116.t001
Figure 1. qRT-PCR validation of ARHGEF3 and RHOA gene knockdown in each cell type. (A) ARHGEF3 mRNA expression in osteoblast-like
cells. (B) RHOA mRNA expression in osteoblast-like cells. (C) ARHGEF3 mRNA expression in osteoclast-like cells. (D) RHOA mRNA expression in
osteoclast-like cells. Data displayed as mean 22DCT 6 SEM from three biological replicates. *P,0.05, **P,0.01.
doi:10.1371/journal.pone.0098116.g001
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(P,0.001). The qRT-PCR results also confirmed the up-regula-
tion of the PTH1R gene in response to RHOA knockdown
observed in the microarray screen (P,0.001); however, neither the
hFOB 1.19 nor the MG-63 cell lines expressed this particular
gene. The qRT-PCR studies showed ARHGEF3 knockdown had a
significant influence on TNFRSF11B expression in the Saos-2 and
hFOB 1.19 cell lines (P= 0.003–0.02), however little influence was
seen in the MG-63 cells. ARHGEF3 knockdown had no consistent
influence on ALPL expression.
Osteoclast Microarray Results
The osteoclastic phenotype of the cells was confirmed by
expression of the genes encoding the osteoclastic biochemical
markers TRAP (ACP5), cathepsin K (CTSK) and calcitonin
receptor (CALCR) from the microarray output. The ACP5 and
CTSK genes were found to be expressed at particularly high levels
in this cell type (mean microarray signal .14,000 fluorescence
units).
Knockdown of the ARHGEF3 and RHOA genes was validated in
the osteoclast-like cells by qRT-PCR prior to microarray analysis.
For the ARHGEF3 and RHOA genes, a mean knockdown of 63%
and 84% was achieved respectively in the osteoclast-like cells from
donor 1 (Fig. 1C and D). Of the 219 candidate genes examined in
this cell type, gene knockdown resulted in significant changes in
expression of 17 genes after adjustment for multiple testing
(Table 2). ARHGEF3 knockdown was found to significantly
influence the expression of 12 genes: CCL5, HLA-C, SNCA, TNF,
OSCAR, CD44, BIRC3, ITGB7, ITGAE, ITGAL, ITGA3 and
ITGAM. For RHOA knockdown, 9 genes were found to be
significantly influenced: TNF, THBS2, CCL5, ITGB7, ARHGDIA,
IGF1, ACTA2, MYL9 and ITGAE. Of these, the effect of RHOA
knockdown on the ACTA2 gene was also observed in the
osteoblast-like cells. Table S2 contains the microarray results for
all of the candidate genes examined in the osteoclast-like cells (P
values corrected for multiple testing).
qRT-PCR Validation and Replication of Microarray Results
for Targeted Genes in Osteoclast-like Cells
In the osteoclast studies, two of the differentially regulated genes
from each of the knockdown experiments were selected for
validation and replication analysis by qRT-PCR in osteoclast-like
cells from 3 additional donors. These included the CCL5 and
OSCAR genes for ARHGEF3 knockdown, and ARHGDIA and
ACTA2 genes for RHOA knockdown (Fig. 3A–D).
For the ARHGEF3 and RHOA genes, 41% and 36% knockdown
was achieved respectively in the donor 2 cells, 52% and 45%
respectively in the donor 3 cells and 25% and 32% respectively in
the donor 4 cells (Fig. 1C and D). The efficiency of knockdown of
ARHGEF3 and RHOA averaged 45.3% and 49.3% respectively in
this cell type, substantially lower than that observed in the
osteoblast-like cells (76.8% vs 49.3% for RHOA, P= 0.07; 78.7% vs
45.3% for ARHGEF3, P= 0.007). The knockdown was consider-
ably lower than desired, however there was some evidence from
the overall analysis to suggest that knockdown of RHOA reduces
Figure 2. qRT-PCR validation of selected genes in response to ARHGEF3 and RHOA gene knockdown in osteoblast-like cells. (A)
TNFRSF11B mRNA expression in osteoblast-like cells. (B) ALPL mRNA expression in osteoblast-like cells. (C) PTH1R mRNA expression in osteoblast-like
cells. (D) ACTA2 mRNA expression in osteoblast-like cells. Data displayed as mean 22DCT 6 SEM from three biological replicates. *P,0.05, **P,0.01.
doi:10.1371/journal.pone.0098116.g002
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the expression of ACTA2 in this cell type (P=0.002 by ANOVA).
RHOA knockdown also caused a significant overall reduction in
ARHGDIA expression in the osteoclast-like cells (P,0.001 by
ANOVA). While some significant changes were seen for cells from
particular donors, the influence of ARHGEF3 knockdown on CCL5
and OSCAR was inconsistent.
Discussion
We previously reported associations between polymorphism in
the RHOA and ARHGEF3 genes and bone density in women and
in this study investigated the potential role of these genes in the
regulation of bone cells. The knockdown of these two genes
showed clear effects on the expression of a number of potentially
relevant genes and pathways in two of the major bone cell types –
osteoblasts and osteoclasts. Greater gene knockdown levels were
achieved in the osteoblast-like cells than in the osteoclast-like cells.
Concerning the studies performed in the osteoblast-like cells,
expression of the ACTA2 gene was found to be significantly down-
regulated by RHOA knockdown in all three osteoblast-like cell lines
examined (Saos-2, hFOB 1.19 and MG-63), with an average
expression ratio of 0.35 seen in knockdown cell cultures relative to
control cell cultures by qRT-PCR. The ACTA2 gene encodes the
alpha 2 actin cytoskeletal protein, which is a major component of
the smooth muscle cell contractile apparatus and accounts for
around 40% of the total protein and around 70% of the total actin
in smooth muscle cells [33,34]. There have been few studies on the
role of the ACTA2 gene product in bone metabolism, however
there is evidence in the literature to suggest that the ACTA2 gene is
regulated by RhoA signalling. Mack et al. [35] found that
expression of constitutively active RhoA in rat smooth muscle
cell cultures increased the activity of the Acta2 promoter, whereas
inhibition of RhoA decreased the activity of the promoter. They
also found that stimulation of actin polymerisation in these smooth
muscle cells increased the activity of the Acta2 promoter by 13-fold
[35]. In addition, Zhao et al. [36] reported that static tensile forces
applied to rat fibroblasts stimulates the promoter activity of the
Acta2 gene through the Rho signalling pathway. Collectively, these
data suggest that expression of the ACTA2 gene may be regulated
through the RhoA signalling pathway, and the results presented
here support this.
Knockdown of the ARHGEF3 gene in both the discovery and
replication experiments with Saos-2 cells resulted in significant
down-regulation of the levels of TNFRSF11B (osteoprotegerin)
mRNA. This effect was replicated in the hFOB 1.19 cells, but not
in the MG-63 cell line. It is not clear why this effect was not seen in
the MG-63 cells, it may be an effect specific to that cell line.
Table 2. Genes significantly influenced in microarray analysis of ARHGEF3 and RHOA gene knockdown in osteoclast-like cells from
donor 1.









ARHGEF3 CCL5 Chemokine ligand 5 4402 588 7.48 ,0.001
HLA-C Major histocompatibility complex,
class I, C
235 87 2.71 ,0.001
SNCA Synuclein, alpha 129 260 0.49 ,0.001
TNF Tumour necrosis
factor alpha
420 156 2.69 ,0.001
OSCAR Osteoclast associated
Ig-like receptor
1950 1244 1.57 0.01
CD44 CD44 molecule 2279 3360 0.68 0.03
BIRC3 Baculoviral IAP repeat-containing 3 496 321 1.55 0.04
ITGB7 Integrin, beta 7 588 106 5.54 ,0.001
ITGAE Integrin, alpha E 256 483 0.53 ,0.001
ITGAL Integrin, alpha L 145 79 1.85 0.003
ITGA3 Integrin, alpha 3 107 221 0.48 0.003
ITGAM Integrin, alpha M 1033 1699 0.61 0.004
RHOA TNF Tumour necrosis
factor alpha
345 156 2.21 ,0.001
THBS2 Thrombospondin 2 89 43 2.05 ,0.001
CCL5 Chemokine ligand 5 891 588 1.52 0.006
ITGB7 Integrin, beta 7 246 106 2.32 ,0.001
ARHGDIA Rho GDP dissociation
inhibitor alpha
579 998 0.58 ,0.001
IGF1 Insulin-like growth factor 1 121 42 2.86 ,0.001
ACTA2 Alpha 2 actin, smooth muscle 545 965 0.56 0.001
MYL9 Myosin, light chain 9, regulatory 22 49 0.46 0.04
ITGAE Integrin, alpha E 342 483 0.71 0.04
Expression ratios are given as expression of the gene in the knockdown cultures relative to the negative control cultures. P adjusted for multiple testing.
*FU, fluorescence units.
doi:10.1371/journal.pone.0098116.t002
Influence of ARHGEF3 and RHOA Knockdown
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TNFRSF11B mRNA levels were significantly higher in the MG-63
cells than in the hFOB 1.19 and Saos-2 cells, in line with studies by
Pautke et al. [37]. There are well described differences in the
expression patterns between osteoblast-like cell lines reported
elsewhere [37–39].
In addition to these findings, knockdown of the RHOA gene in
both the discovery and replication batches of Saos-2 cells resulted
in significant up-regulation of PTH1R (parathyroid hormone 1
receptor) mRNA levels, although expression of this gene was not
detected in the hFOB 1.19 or MG-63 cell lines. Both PTH1R and
TNFRSF11B have a major role in the stimulation of osteoclasto-
genesis upon exposure to parathyroid hormone (PTH), suggesting
that the ARHGEF3 and RHOA genes may be involved in this
process. Radeff et al. [40] found that treatment of UMR-106 rat
osteoblast-like cells with Clostridium difficile toxin B, which
specifically inhibits the Rho proteins (including RhoA) through
glucosylation of the nucleotide binding site [41], reduced PTH-
induced expression of the Il6 gene, the product of which has been
shown to promote osteoclastogenesis [42]. The authors concluded
that the Rho proteins are an important component of PTH
signalling in osteoblasts and may have a role in the activation of
the intracellular messenger protein kinase C alpha [40]. Another
study published by Wang and Stern [43] found that UMR-106 rat
osteoblast-like cells transfected with dominant negative RhoA and
treated with PTH and/or calcitriol increased production of
TNFSF11 mRNA (encoding RANKL) and reduced production
of TNFRSF11B mRNA, stimulating osteoclastogenesis of co-
cultured RAW 264.7 mouse monocyte/macrophage-like cells
[43]. However, when these cells were transfected with constitu-
tively active RhoA and treated with PTH and/or calcitriol, the
levels of TNFSF11 and TNFRSF11B mRNA did not change
significantly and osteoclastogenesis of the RAW 264.7 cells failed
to occur [43]. These results led the authors to suggest that RhoA
signalling can inhibit hormone-stimulated osteoclastogenesis
through effects on RANKL and osteoprotegerin expression in
osteoblasts [43]. No consistent effect of ARHGEF3 knockdown on
ALPL expression could be found, however a higher expression of
this gene in Saos-2 cells was found compared to the other cells
investigated, including the MG-63 cells, in line with the findings of
Pautke et al. [37].
One limitation of the gene expression data in the osteoclast-like
cells was that consistently high gene knockdown (.60%) was not
achieved in some of our experiments, and a greater level of
knockdown may show more substantial changes than seen in our
studies. Nevertheless, some interesting results were obtained.
Expression of the ARHGDIA and ACTA2 genes was found to be
significantly reduced in response to RHOA gene knockdown. The
product of the ARHGDIA gene is a Rho GDP dissociation inhibitor
(GDI) which acts as a negative regulator of several of the
RhoGTPases [44]. RhoGDIs maintain the Rho proteins in their
inactive GDP-bound state by inhibiting the exchange of GDP for
GTP [45] and by restricting membrane anchoring [46]. The
Figure 3. qRT-PCR validation of selected genes in response to ARHGEF3 and RHOA gene knockdown in osteoclast-like cells. (A) CCL5
mRNA expression in osteoclast-like cells. (B) OSCARmRNA expression in osteoclast-like cells. (C) ARHGDIAmRNA expression in osteoclast-like cells. (D)
ACTA2 mRNA expression in osteoclast-like cells. Data displayed as mean 22DCT 6 SEM from three biological replicates. *P,0.05, **P,0.01, {
determined as significant by ANOVA.
doi:10.1371/journal.pone.0098116.g003
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down-regulation of ARHGDIA expression seen in the RHOA
knockdown osteoclast-like cells in this study could be a compen-
satory mechanism for the reduced expression of the RHOA gene.
The influence of RHOA knockdown on expression of the ACTA2
gene adds further support to the earlier suggestion that expression
of this gene is regulated by the RhoA signalling pathway.
In conclusion, knockdown of the ARHGEF3 and RHOA genes in
bone cells of human origin reveals important regulatory changes
including significant down-regulation of the ACTA2 gene, encod-
ing the cytoskeletal protein alpha 2 actin, in both osteoblast-like
and osteoclast-like cells in response to RHOA knockdown. RHOA
knockdown also resulted in up-regulation of the PTH1R gene in
the Saos-2 osteoblast-like cell line and down-regulation of
ARHGDIA in osteoclast-like cells, whereas ARHGEF3 knockdown
caused down-regulation of the TNFRSF11B gene in the Saos-2 and
hFOB 1.19 osteoblast-like cells. These findings add further
evidence to previous studies suggesting a role for the RHOA and
ARHGEF3 genes in bone metabolism. Future work in this area
could include confirmatory studies investigating the influence of
over-expression of the ARHGEF3 and RHOA genes in these cell
types and examination of effects at the protein level.
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